Table 3 Endorsement of adverse subjective effects to cannabis by decade in community-based athletes
Negative subject effects | 21 to 29 (N = 47) | 30 to 39 (N = 74) | 40 to 49 (N = 81) | 50 to 59 (N = 61) | ≥60 (n = 38) | P value for trend |
|---|---|---|---|---|---|---|
N (%) | ||||||
Anxiety | 21 (44.7) | 23 (31.1) | 11 (13.6) | 7 (11.5) | 1 (2.6) | < 0.001 |
Increased appetite | 18 (38.3) | 25 (33.8) | 12 (14.8) | 10 (16.4) | 8 (21.1) | 0.002 |
Difficulty concentrating | 14 (29.8) | 12 (16.2) | 10 (12.3) | 8 (13.1) | 6 (15.8) | 0.063 |
Cardiovascular | 9 (19.1) | 8 (10.8) | 1 (1.2) | 3 (4.9) | 0 (0.0) | < 0.001 |
Respiratory | 8 (17.0) | 19 (25.7) | 6 (7.4) | 8 (13.1) | 3 (7.9) | 0.002 |
Gastrointestinal | 5 (10.6) | 4 (5.4) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0.001 |
Worse athletic performance | 1 (2.1) | 7 (9.5) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0.003 |
Skin reaction | 0 (0.0) | 1 (1.4) | 2 (2.5) | 0 (0.0) | 0 (0.0) | 0.81 |